Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
Authors:
- Ove AlmkvistOAOve Almkvist
- Anton ForsbergAFAnton Forsberg
- Göran HagmanGHGöran Hagman
- Marie LärksäterMLMarie Lärksäter
- 14 May 2008
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 63 (5) , 621-631
Abstract
Objective: The effects of (−)‐phenserine (phenserine) and placebo/donepezil treatment on regional cerebral metabolic rate for glucose (rCMRglc) and brain amyloid load were investigated by positron emission tomography in 20 patients with mild Alzheimer's disease in relation to cerebrospinal fluid (CSF) and plasma biomarkers, and cognitive function.Methods: The first 3 months of the study was a randomized, double‐blind, placebo‐controlled phase, during which 10 patients received phenserine (30mg/day) and 10 patients the placebo. Three to 6 months was an open‐label extension phase, during which the placebo group received donepezil (5mg/day) and the phenserine group remained on phenserine. After 6 months, all patients received phenserine treatment up to 12 months. The patients underwent positron emission tomography examinations to measure rCMRglc (18F‐FDG) and amyloid load (11C‐PIB) at baseline and after 3 and 6 months of the treatment. Neuropsychological and biomarker data were collected at the three times of positron emission tomography imaging.Results: Statistically significant effects on a composite neuropsychological test score were observed in the phenserine‐treated group compared with the placebo and donepezil group at 3 and 6 months, respectively. Values of rCMRglc were significantly increased in several cortical regions after 3 months of phenserine treatment, compared with baseline, and correlated positively with cognitive function and CSF β‐amyloid 40 (Aβ40). Cortical Pittsburgh Compound B retention correlated negatively with CSF Aβ40 levels and the ratio Aβ/β‐secretase–cleaved amyloid precursor protein. In CSF, Aβ40 correlated positively with the attention domain of cognition.Interpretation: Phenserine treatment was associated with an improvement in cognition and an increase in rCMRglc. Ann Neurol 2008Keywords
This publication has 46 references indexed in Scilit:
- Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserineProceedings of the National Academy of Sciences, 2007
- The importance of impaired physical health and age in normal cognitive agingScandinavian Journal of Psychology, 2007
- The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and MiceThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s diseaseJournal of Neural Transmission, 2005
- Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell linesJournal of Neurochemistry, 2004
- Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patientsEuropean Journal of Neurology, 2004
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasmaAmyloid, 2000
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984